Karachi: Citi Pharma Limited, a prominent player in the pharmaceutical sector, has disclosed recent share transactions executed by its directors and key stakeholders in compliance with PSX regulation 5.6.4. The report, dated March 30, 2026, details substantial trading activities involving non-executive directors Saira Aslam, Nadeem Amjad, and Muhammad Naeem.

According to information available from the Pakistan Stock Exchange (PSX), Saira Aslam, a non-executive director, executed multiple transactions affecting her shareholding in the company. On December 8, 2025, she purchased 500,000 shares without a specified rate, marking a cumulative percentage of 0.24. Subsequently, she sold 82,500 shares on January 9, 2026, at a rate of 87.684570, resulting in a cumulative percentage of 0.20. Further actions included selling 417,500 shares on February 3, 2026, and buying 60,000 shares on February 18, 2026, at a rate of 89.00, bringing her cumulative percentage to 0.04. Her trading continued with a purchase of 50,000 shares on March 19, 2026, at 72.88, and an additional 10,000 shares on March 24, 2026, at 73.45, maintaining a cumulative percentage of 0.07.

In a separate transaction, Nadeem Amjad, another non-executive director, sold 402,000 shares on November 25, 2025, at a rate of 83.25, culminating in a cumulative shareholding of 27.45 million, which represents a significant holding of 12.02%.

Muhammad Naeem, also a non-executive director, significantly increased his holdings through a series of purchases. On November 25, 2025, he acquired 902,000 shares at 84.30, bringing his cumulative holdings to 15.75 million shares, equivalent to 6.89%. He continued his buying spree with 500,000 shares on November 26, 2025, at 84.56, and 800,000 shares on November 27, 2025, at 86.58, resulting in a cumulative percentage of 7.46%.

These activities indicate strategic moves by the company’s directors, reflecting their confidence in Citi Pharma Limited’s market position and future prospects.